Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5% ...

The latest health-related developments include Merck's acquisition talks with SpringWorks, disbandment of a US Justice ...

As tariffs loom over the sector, biotechs with U.S.-based manufacturing and intellectual property are soothing investor ...

Recent health news highlights Germany's Merck's acquisition talks with SpringWorks, U.S. Justice Department's disbanding of a ...

Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold ...

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Merck & Co., Inc. (MRK) is currently at $82.84, up $3.00 or 3.76% --Would be highest close since April 3, 2025, when it closed at $86.39 --On pace for largest percent increase since March 27, 2024, ...

Scores of FDA employees are searching for an exit from an agency in turmoil, especially staffers tasked with reviewing drug ...

Robert F. Kennedy Jr. and I rarely see eye to eye, but I’ll grudgingly admit he’s not entirely wrong about food dyes, though ...

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...